Cyclerion Therapeutics, Inc.
CYCN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $875 | $93 | $81 | $1,806 |
| % Growth | 840.9% | 14.8% | -95.5% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $875 | $93 | $81 | $1,806 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $348 | $56 | $36 | $56 |
| G&A Expenses | $1,533 | $1,709 | $1,502 | $1,248 |
| SG&A Expenses | $1,533 | $1,709 | $1,502 | $1,248 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $1,881 | $1,765 | $1,538 | $1,304 |
| Operating Income | -$1,006 | -$1,672 | -$1,457 | $502 |
| % Margin | -115% | -1,797.8% | -1,798.8% | 27.8% |
| Other Income/Exp. Net | $30 | $1,348 | $28 | $28 |
| Pre-Tax Income | -$976 | -$324 | -$1,429 | $530 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$976 | -$324 | -$1,429 | $530 |
| % Margin | -111.5% | -348.4% | -1,764.2% | 29.3% |
| EPS | -0.3 | -0.11 | -0.56 | 0.21 |
| % Growth | -172.7% | 80.4% | -366.7% | – |
| EPS Diluted | -0.3 | -0.11 | -0.56 | 0.21 |
| Weighted Avg Shares Out | 3,225 | 3,071 | 2,556 | 2,546 |
| Weighted Avg Shares Out Dil | 3,225 | 3,071 | 2,556 | 2,546 |
| Supplemental Information | – | – | – | – |
| Interest Income | $30 | $31 | $28 | $28 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$976 | -$1,672 | -$1,457 | $502 |
| % Margin | -111.5% | -1,797.8% | -1,798.8% | 27.8% |